Safety Alert - Baraclude, entecavir tablets and oral solution
AIDS (Acquired Immunodeficiency Syndrome or Acquired Immune Deficiency Syndrome, sometimes written Aids) is a human disease characterized by progressive destruction of the body's immune system. It is widely accepted that AIDS results from infection with HIV (Human Immunodeficiency Virus).
Safety Alert - Baraclude, entecavir tablets and oral solution

HIV :: Safety Alert - Baraclude, entecavir tablets and oral solution
Healthcare professionals are advised that when considering therapy with Baraclude in an HIV/HBV co-infected patient not receiving HAART, the risk of developing HIV resistance cannot be excluded based on current information.
FDA and Bristol-Myers Squibb notified healthcare professionals of revisions to the MICROBIOLOGY/Antiviral Activity and INDICATIONS AND USAGE/Description of Clinical Studies/Special Populations sections of the prescribing information for Baraclude. The revised labeling is the result of a case report in which a human immunodeficiency virus (HIV) variant containing the M184V resistance substitution was documented during Baraclude treatment for chronic hepatitis B virus (HBV) infection in an HIV/HBV co-infected patient who was not simultaneously receiving highly active antiretroviral therapy (HAART).
Current treatment guidelines recommend Baraclude as an option for treatment of HBV in the HIV/HBV co-infected adult patient who does not qualify for HAART. Healthcare professionals are advised that when considering therapy with Baraclude in an HIV/HBV co-infected patient not receiving HAART, the risk of developing HIV resistance cannot be excluded based on current information.
(
HIV :: Safety Alert - Baraclude, entecavir tablets and oral solution published at
SpiritIndia on Sunday, February 25, 2007)
Search more information on
HIVRecently posted related articles on HIV :
- HIV :: A hairpin to fight HIV
- HIV :: Testing delays cause severe AIDS complications, Einstein researchers find
- HIV :: HIV-TB spreads in Africa, undermines control of world's 2 deadliest infectious diseases
- HIV :: HIV patients sicker when seeking care than in the past
- HIV :: UN refugee agency launches HIV/AIDS awareness project in Nepal
- HIV :: A low prevalence of H pylori in HIV-positive patients
- HIV :: HIV linked to increased risk of ESRD in African-Americans
- HIV :: FDA approves new HIV drug raltegravir tablets
- HIV :: Many Africans don't continue HIV AIDS treatment
- HIV :: FDA approves Merck's Isentress, raltegravir tablets for HIV AIDS
»»
Anemia :: Roche suspends enrollment for anemia drug trial««
Alcohol :: Skills training program can reduce alcohol consumptionThe information provided on
SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information.
Health,
Business,
Science,
Sports,
Entertainment,
Technology
©2002-2009 SpiritIndia.com